Expanding Pediatric Genomics Will Transform Rare Disease Diagnostics

Analysts have raised their price target for GeneDx Holdings from $104.61 to $113.86, citing the company's accelerating growth and first-mover advantage in rare disease diagnostics, a looming profitability inflection, and favorable shifts in pediatric testing standards. Analyst Commentary Bullish analysts highlight GeneDx as a fast-growing player in the under-penetrated rare disease testing market.